MDT-AP-2589
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 21.96
- os_event
- false
- age_years
- 9
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.44063162
- umap2_2d
- -9.17437988
- umap1_3d
- -3.018030523
- umap2_3d
- -1.615297778
- umap3_3d
- 5.035479443
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- COAGULATION+0.370
- ALLOGRAFT_REJECTION+0.360
- MYC_TARGETS_V2+0.360
- IL6_JAK_STAT3_SIGNALING+0.340
- INFLAMMATORY_RESPONSE+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
- APICAL_SURFACE+0.330
Top 10 suppressed
- PROTEIN_SECRETION-0.300
- PI3K_AKT_MTOR_SIGNALING-0.240
- ANDROGEN_RESPONSE-0.220
- HEME_METABOLISM-0.220
- TGF_BETA_SIGNALING-0.170
- MITOTIC_SPINDLE-0.130
- UNFOLDED_PROTEIN_RESPONSE-0.070
- G2M_CHECKPOINT-0.030
- MTORC1_SIGNALING-0.030
- SPERMATOGENESIS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2131 | Med | Medulloblastoma | 0.866 |
| 2 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.846 |
| 3 | SRR1313163 | — | D | 0.842 |
| 4 | BS_X23724NJ | high-grade glioma | — | 0.825 |
| 5 | d6b7de60-321d-4f6d-82e7-3d5e9598462c | — | — | 0.820 |
| 6 | C3L-02951 | — | cohortSQ1 | 0.817 |
| 7 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.816 |
| 8 | TCGA-BH-A0RX-01A-21R-A084-07 | — | D | 0.816 |
| 9 | TCGA-E9-A1NC-01A-21R-A26B-07 | — | E | 0.815 |
| 10 | MDT-AP-0821 | Med | Medulloblastoma | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |